LYPD1 Inhibitors
Chemical inhibitors of LYPD1 include a variety of compounds that target different molecular pathways. Marimastat and Batimastat, both matrix metalloprotease inhibitors, can inhibit the proteolytic activity that LYPD1 is involved in, as LYPD1 is part of the Ly6/uPAR family which plays a role in cellular processes like cell adhesion and motility. The functional inhibition of LYPD1 by these MMP inhibitors might be due to the prevention of extracellular matrix degradation, a process in which LYPD1 could participate either directly or indirectly. Ilomastat, another MMP inhibitor, can impede the degradation of the extracellular matrix, potentially restricting LYPD1's ability to interact with its surroundings and thus inhibiting its function.
Other chemicals, such as GW 5074 and PD 98059, target the MAPK/ERK pathway, which is a key signaling route for cell differentiation and proliferation. GW 5074, a c-Raf kinase inhibitor, can diminish the signal transduction processes that LYPD1 may be involved with, while PD 98059 specifically inhibits MEK, an upstream component of the MAPK pathway, and can suppress the cellular responses that involve LYPD1. SP600125 and SB 203580 are inhibitors of the JNK and p38 MAP kinase, respectively. By inhibiting these kinases, they can reduce the signaling pathways associated with inflammation and cell differentiation that LYPD1 may participate in. LY294002 and Wortmannin are PI3K inhibitors that can decrease AKT signaling, potentially leading to the functional inhibition of LYPD1 in related cell survival and growth pathways. U0126, another MEK1/2 inhibitor, can prevent the activation of signaling pathways in which LYPD1 is involved. Lastly, Rapamycin and PP242, which are mTOR inhibitors, can inhibit the mTOR pathway, a central regulator of cell growth and proliferation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Marimastat | 154039-60-8 | sc-202223 sc-202223A sc-202223B sc-202223C sc-202223E | 5 mg 10 mg 25 mg 50 mg 400 mg | $168.00 $218.00 $404.00 $629.00 $4900.00 | 19 | |
Marimastat is a broad-spectrum matrix metalloprotease (MMP) inhibitor. Since LYPD1 is a member of the Ly6/uPAR family, which can be involved in proteolytic processing, marimastat can inhibit the proteolytic activity where LYPD1 is involved, leading to its functional inhibition. | ||||||
Batimastat | 130370-60-4 | sc-203833 sc-203833A | 1 mg 10 mg | $179.00 $377.00 | 24 | |
Batimastat is another MMP inhibitor. It can inhibit the extracellular matrix degradation, potentially inhibiting the functional activity of LYPD1, which might be involved in cell adhesion and motility. | ||||||
GM 6001 | 142880-36-2 | sc-203979 sc-203979A | 1 mg 5 mg | $77.00 $270.00 | 55 | |
Ilomastat, also known as GM6001, is an MMP inhibitor that can prevent the degradation of the extracellular matrix. By doing so, ilomastat may inhibit the functional interaction of LYPD1 with its extracellular environment. | ||||||
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
GW 5074 is a potent inhibitor of the c-Raf kinase, which is part of the MAPK/ERK pathway. By inhibiting this pathway, GW 5074 can decrease the signal transduction processes that LYPD1 may be involved in. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a specific inhibitor of MEK, which is upstream of ERK in the MAPK pathway. It can inhibit the signaling leading to cellular responses where LYPD1 is active. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of the c-Jun N-terminal kinase (JNK), part of the MAPK pathway. By inhibiting JNK, SP600125 can reduce the functional activity of LYPD1 in signal transduction. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 selectively inhibits p38 MAP kinase, which is involved in inflammatory responses and cell differentiation. Inhibition of p38 MAP kinase can reduce the cellular processes in which LYPD1 is involved. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. By inhibiting PI3K, it can reduce the downstream AKT signaling, which can result in the functional inhibition of LYPD1 in related signal transduction pathways. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent PI3K inhibitor. By inhibiting PI3K, wortmannin can decrease the downstream signaling that may include LYPD1, leading to its functional inhibition. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which is upstream of ERK in the MAPK pathway. By inhibiting MEK1/2, U0126 can prevent the activation of signaling pathways involving LYPD1. | ||||||